Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies.
Journal
Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673
Informations de publication
Date de publication:
03 06 2022
03 06 2022
Historique:
received:
15
03
2022
accepted:
16
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
Based on immunostainings and biochemical analyses, certain post-translationally modified alpha-synuclein (aSyn) variants, including C-terminally truncated (CTT) and Serine-129 phosphorylated (pSer129) aSyn, are proposed to be involved in the pathogenesis of synucleinopathies such as Parkinson's disease with (PDD) and without dementia (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). However, quantitative information about aSyn proteoforms in the human brain in physiological and different pathological conditions is still limited. To address this, we generated sequential biochemical extracts of the substantia nigra, putamen and hippocampus from 28 donors diagnosed and neuropathologically-confirmed with different synucleinopathies (PD/PDD/DLB/MSA), as well as Alzheimer's disease, progressive supranuclear palsy, and aged normal subjects. The tissue extracts were used to build a reverse phase array including 65 aSyn antibodies for detection. In this multiplex approach, we observed increased immunoreactivity in donors with synucleinopathies compared to controls in detergent-insoluble fractions, mainly for antibodies against CT aSyn and pSer129 aSyn. In addition, despite of the restricted sample size, clustering analysis suggested disease-specific immunoreactivity signatures in patient groups with different synucleinopathies. We aimed to validate and quantify these findings using newly developed immunoassays towards total, 119 and 122 CTT, and pSer129 aSyn. In line with previous studies, we found that synucleinopathies shared an enrichment of post-translationally modified aSyn in detergent-insoluble fractions compared to the other analyzed groups. Our measurements allowed for a quantitative separation of PDD/DLB patients from other synucleinopathies based on higher detergent-insoluble pSer129 aSyn concentrations in the hippocampus. In addition, we found that MSA stood out due to enrichment of CTT and pSer129 aSyn also in the detergent-soluble fraction of the SN and putamen. Together, our results achieved by multiplexed and quantitative immunoassay-based approaches in human brain extracts of a limited sample set point to disease-specific biochemical aSyn proteoform profiles in distinct neurodegenerative disorders.
Identifiants
pubmed: 35659116
doi: 10.1186/s40478-022-01382-z
pii: 10.1186/s40478-022-01382-z
pmc: PMC9164351
doi:
Substances chimiques
Detergents
0
alpha-Synuclein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
82Informations de copyright
© 2022. The Author(s).
Références
Brain Pathol. 2008 Oct;18(4):484-96
pubmed: 18371174
J Biol Chem. 2006 Oct 6;281(40):29739-52
pubmed: 16847063
Science. 1997 Jun 27;276(5321):2045-7
pubmed: 9197268
PLoS One. 2016 Mar 16;11(3):e0151615
pubmed: 26982086
J Neurosci. 2006 Apr 12;26(15):3942-50
pubmed: 16611810
Nat Cell Biol. 2002 Feb;4(2):160-4
pubmed: 11813001
J Biol Chem. 2012 May 4;287(19):15345-64
pubmed: 22315227
J Neurochem. 2019 Apr;149(1):126-138
pubmed: 30125936
Elife. 2018 Jul 03;7:
pubmed: 29969391
J Neuropathol Exp Neurol. 2003 Oct;62(10):1060-75
pubmed: 14575241
Ann Clin Transl Neurol. 2022 Feb;9(2):106-121
pubmed: 35060360
Front Neurol. 2021 Oct 01;12:705407
pubmed: 34659081
JAMA Neurol. 2018 Oct 1;75(10):1206-1214
pubmed: 29913017
Science. 2003 Oct 31;302(5646):841
pubmed: 14593171
Cold Spring Harb Perspect Med. 2018 Mar 1;8(3):
pubmed: 28108534
J Lipid Res. 2011 Dec;52(12):2323-2331
pubmed: 21971713
PLoS One. 2017 May 31;12(5):e0178576
pubmed: 28562630
Neuroscience. 1996 Aug;73(4):979-87
pubmed: 8809817
Langmuir. 2020 May 5;36(17):4671-4681
pubmed: 32271585
Brain. 2015 Aug;138(Pt 8):2116-9
pubmed: 26205836
J Neuropathol Exp Neurol. 2000 Aug;59(8):733-48
pubmed: 10952063
Ann Neurol. 2009 May;65(5):610-4
pubmed: 19475667
Neurosci Lett. 2003 Oct 2;349(2):133-5
pubmed: 12946570
Am J Pathol. 2001 Dec;159(6):2215-25
pubmed: 11733371
Acta Neuropathol. 2021 Sep;142(3):423-448
pubmed: 34115198
Nat Genet. 1998 Feb;18(2):106-8
pubmed: 9462735
Lancet. 2004 Sep 25-Oct 1;364(9440):1167-9
pubmed: 15451224
Acta Neuropathol Commun. 2021 Aug 28;9(1):146
pubmed: 34454615
Neurology. 1997 Dec;49(6):1570-6
pubmed: 9409348
Oncogene. 2001 Apr 12;20(16):1981-9
pubmed: 11360182
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469-73
pubmed: 9600990
Brain Commun. 2020;2(1):fcaa010
pubmed: 32280944
Neurology. 2000 May 23;54(10):1916-21
pubmed: 10822429
Am J Pathol. 1999 Oct;155(4):1241-51
pubmed: 10514406
J Biol Chem. 2013 Mar 1;288(9):6371-85
pubmed: 23319586
J Proteome Res. 2019 May 3;18(5):2109-2120
pubmed: 30943367
Acta Neuropathol. 2001 Oct;102(4):355-63
pubmed: 11603811
Neurosci Lett. 1998 Jun 19;249(2-3):180-2
pubmed: 9682846
Alzheimers Res Ther. 2014 Dec 01;6(5-8):77
pubmed: 25452767
Sci Rep. 2020 Aug 19;10(1):14014
pubmed: 32814795
PLoS Genet. 2014 May 08;10(5):e1004302
pubmed: 24810576
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
Mov Disord. 2017 Feb;32(2):211-218
pubmed: 27886407
Neuroscience. 2012 Jan 3;200:106-19
pubmed: 22079575
Am J Pathol. 2013 Mar;182(3):940-53
pubmed: 23313024
J Parkinsons Dis. 2017;7(s1):S51-S69
pubmed: 28282814
N Engl J Med. 2015 Apr 2;372(14):1375-6
pubmed: 25830435
J Neuropathol Exp Neurol. 2017 Jan 1;76(1):2-15
pubmed: 28069931
J Biol Chem. 2000 Jan 7;275(1):390-7
pubmed: 10617630
J Neurochem. 2019 Sep;150(5):475-486
pubmed: 31269263
Ann Neurol. 2004 Feb;55(2):164-73
pubmed: 14755719
J Neuropathol Exp Neurol. 2007 Jan;66(1):35-46
pubmed: 17204935
J Phys Chem B. 2012 Apr 19;116(15):4417-24
pubmed: 22439820
J Mol Biol. 2010 Aug 6;401(1):115-33
pubmed: 20540950
NPJ Parkinsons Dis. 2021 Jul 26;7(1):65
pubmed: 34312398
J Neurochem. 2001 Jan;76(1):87-96
pubmed: 11145981
Nat Neurosci. 2019 Jul;22(7):1099-1109
pubmed: 31235907
Acta Neuropathol. 2011 Jun;121(6):695-704
pubmed: 21400129
Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):E3945-54
pubmed: 23983262
Mol Neurodegener. 2016 Aug 22;11(1):61
pubmed: 27549140
Commun Biol. 2020 Mar 5;3(1):101
pubmed: 32139796
Ann Hum Genet. 2010 Mar;74(2):97-109
pubmed: 20070850
Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2162-7
pubmed: 15684072
Mov Disord. 2013 Jun;28(6):811-3
pubmed: 23457019
Ann Neurol. 2013 Apr;73(4):459-71
pubmed: 23526723
Brain. 2015 Aug;138(Pt 8):2293-309
pubmed: 25981961
Brain Pathol. 2012 Nov;22(6):811-25
pubmed: 22452578
PLoS One. 2014 Feb 04;9(2):e86184
pubmed: 24503933
Brain Pathol. 2012 Nov;22(6):745-56
pubmed: 22369130
J Mol Biol. 2006 Dec 15;364(5):1061-72
pubmed: 17054982
Nature. 2018 May;557(7706):558-563
pubmed: 29743672
Sci Transl Med. 2016 Jul 20;8(348):348ra96
pubmed: 27440727
Neurobiol Aging. 2014 Sep;35(9):2180.e1-5
pubmed: 24746362
Mol Biol Cell. 2013 Jun;24(11):1649-60, S1-3
pubmed: 23576548
Hum Mol Genet. 2019 Jan 1;28(1):31-50
pubmed: 30219847
Brain. 2014 Sep;137(Pt 9):2493-508
pubmed: 25062696
Neuropathol Appl Neurobiol. 2019 Oct;45(6):597-608
pubmed: 30422353
Am J Pathol. 1998 Apr;152(4):879-84
pubmed: 9546347
Sci Rep. 2015 Oct 29;5:15709
pubmed: 26511732
Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S62-7
pubmed: 24262191
Brain. 2004 Dec;127(Pt 12):2657-71
pubmed: 15509623
J Neural Transm (Vienna). 2015 Jul;122(7):937-40
pubmed: 25578485
Neuron. 2018 Aug 22;99(4):781-799.e10
pubmed: 30078578
Am J Pathol. 2007 May;170(5):1725-38
pubmed: 17456777
Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9587-92
pubmed: 27482083
Acta Neuropathol. 2006 Feb;111(2):101-8
pubmed: 16482476
J Neurosci. 2014 Jul 9;34(28):9441-54
pubmed: 25009275
Neurosci Lett. 1998 Jul 31;251(3):205-8
pubmed: 9726379
Neurobiol Dis. 2019 Jan;121:205-213
pubmed: 30236861
Neurology. 2007 Mar 20;68(12):916-22
pubmed: 17251522
Acta Neuropathol. 2009 Jun;117(6):635-52
pubmed: 19330340